Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Adding cetuximab to afatinib provides no benefit in EGFR-mutant NSCLC
Key clinical point: Afatinib plus cetuximab demonstrated no benefit over afatinib alone in previously untreated patients with EGFR-mutant non–small cell lung cancer.
Major finding: The median progression-free survival was 11.9 months in the afatinib/cetuximab group and 13.4 months in the afatinib-alone group (hazard ratio, 1.01; 95% confidence interval, 0.72-1.43; P = .94).
Study details: A phase 2 trial of 168 eligible patients without prior treatment of advanced disease.
Disclosures: The trial was supported by Boehringer Ingelheim, Eli Lilly, grants from the National Institutes of Health/National Cancer Institute, The Hope Foundation Career Development Award, and the SWOG and NIH Yale SPORE in Lung Cancer Grant. The study authors disclosed relationships with many pharmaceutical companies.
Goldberg SB et al. J Clin Oncol. 2020 Oct 6. doi: 10.1200/JCO.20.01149.